MOESM2 of The REal Life EVidence AssessmeNt Tool (RELEVANT): development of a novel quality assurance asset to rate observational comparative effectiveness research studies
posted on 2019-03-27, 05:00authored byJonathan Campbell, Robert Perry, Nikolaos Papadopoulos, Jerry Krishnan, Guy Brusselle, Alison Chisholm, Leif Bjermer, Michael Thomas, Eric Ganse, Maarten Berge, Jennifer Quint, David Price, Nicolas Roche
Additional file 2. This maps the quality recommendations within the primary reference papers Berger et al and Roche et al that resulted in an initial 43-item checklist.
Funding
European Academy of Allergy and Clinical Immunology